X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accesswire.com/724162/Relief-Therapeutics-Announces-Six-Month-Stability-Data-on-a-New-Formulation-of-RLF-100-Aviptadil
https://www.accesswire.com/710682/Relief-Therapeutics-Announces-Promising-Initial-Stability-Data-on-a-New-Formulation-of-RLF-100R-Aviptadil
https://www.fiercebiotech.com/biotech/deja-vu-fda-rejects-nrx-filing-emergency-use-covid-19
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-provides-update-on-breakthrough-therapy-designation-btd-request-for-zyesami-aviptadil-301566128.html
https://www.fiercebiotech.com/biotech/activ-nrx-tanks-peptide-fails-nih-trial-severe-covid-19-patients
https://www.clinicaltrialsarena.com/news/nrx-zyesami-covid-futility/
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-files-new-breakthrough-therapy-designation-request-for-zyesami-aviptadil-in-subgroup-of-patients-with-critical-covid-19-with-respiratory-failure-that-were-also-treated-with-remdesivir-and-continued-to-progre-301530082.html
https://www.prnewswire.com/news-releases/i-spy-covid-trial-sponsored-by-quantum-leap-healthcare-collaborative-suggests-no-clinical-benefit-with-addition-of-nebulized-zyesami-aviptadil-when-given-by-mouth-inhalation-in-critically-ill-patients-with-covid-19-301514508.html
https://www.globenewswire.com/news-release/2022/01/18/2368234/0/en/NRx-Pharmaceuticals-Announces-Expansion-of-ZYESAMI-aviptadil-US-Expanded-Access-and-Right-to-Try-Programs-for-Patients-with-COVID-19-Respiratory-Failure-who-have-Exhausted-All-Appr.html
https://www.pharmaceutical-technology.com/news/nrx-breakthrough-therapy-designation-covid-19/
https://www.clinicaltrialsarena.com/news/nrx-encouraging-safety-zyesami-trial/
https://www.globenewswire.com/news-release/2021/12/14/2351487/0/en/NRx-Pharmaceuticals-Announces-New-Favorable-Safety-Report-for-ZYESAMI-aviptadil-in-NIH-Sponsored-ACTIV-3b-Critical-Care-Study-in-Patients-with-Life-Threatening-COVID-19.html
https://www.globenewswire.com/news-release/2021/11/29/2341962/0/en/NRx-Pharmaceuticals-Identifies-Significantly-Higher-Likelihood-of-Surviving-and-Recovering-from-Critical-COVID-19-in-ZYESAMI-aviptadil-Treated-Patients-Previously-Administered-Remd.html
https://www.globenewswire.com/news-release/2021/11/11/2332559/0/en/NRx-Pharmaceuticals-Receives-US-Food-and-Drug-Administration-Review-of-ZYESAMI-aviptadil-Manufacturing-Information.html
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-declines-emergency-use-authorization-for-zyesami-aviptadil-for-patients-with-critical-covid-19-with-respiratory-failure-301417228.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-favorable-new-safety-report-for-zyesami-aviptadil-in-nih-sponsored-activ-3b-critical-care-study-in-patients-with-life-threatening-covid-19-301414333.html
https://seekingalpha.com/news/3752107-nrx-pharma-up-35-on-supply-arrangement-for-covid-19-respiratory-failure-candidate
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-progress-on-worldwide-commercial-scale-development-of-zyesami-aviptadil-301397710.html
https://www.clinicaltrialsarena.com/news/nrx-zyesami-covid-study/
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-improved-survival-at-one-year-in-highly-comorbid-covid-19-patients-treated-with-zyesami-aviptadil-301385474.html
https://www.relieftherapeutics.com/newsblog/relief-therapeutics-provides-update-on-regulatory-interactions-in-the-united-kingdom-and-european-union-relating-to-lead-drug-candidate-rlf-100-aviptadil
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-initiation-of-emergency-use-training-and-extension-of-phase-23-inhaled-zyesami-aviptadil-acetate-trial-in-the-nation-of-georgia-301326019.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-initiation-of-emergency-use-training-and-extension-of-phase-23-inhaled-zyesami-aviptadil-acetate-trial-in-the-nation-of-georgia-301326019.html
https://www.expresspharma.in/biophore-applies-for-dcgi-approval-for-emergency-use-of-aviptadil-to-treat-covid-19/
https://www.biospace.com/article/releases/relief-confirms-release-of-60-day-findings-from-phase-2b-3-clinical-trial-of-intravenous-rlf-100-tm-aviptadil-/#:~:text=GENEVA%2C%20SWITZERLAND%20%2F%20ACCESSWIRE%20%2F%20March,of%2060%2Dday%20results%20from
https://www.prnewswire.com/news-releases/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failure-in-critically-ill-patients-with-covid-19-treated-with-high-flow-nasal-oxygen-at-28-day-interim-endpoint-301233805.html
https://www.clinicaltrialsarena.com/news/neurorx-zyesami-recovery-trial/
https://www.prnewswire.com/news-releases/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failure-in-critically-ill-patients-with-covid-19-treated-with-high-flow-nasal-oxygen-at-28-day-interim-endpoint-301233805.html
https://www.prnewswire.com/news-releases/neurorx-reports-initial-phase-2b3-study-results-demonstrating-significant-benefit-of-zyesami-aviptadil-in-reducing-hospital-stay-among-patients-with-respiratory-failure-due-to-critical-covid-19-301224915.html
https://www.prnewswire.com/news-releases/neurorx-initiates-phase-23-study-of-inhaled-zyesami-for-severe-covid-19-with-uci-health-301221615.html#:~:text=RADNOR%2C%20Pa.%20and%20IRVINE%2C,the%20University%20of%20California%2C%20Irvine.
https://www.prnewswire.com/news-releases/neurorx-and-relief-announce-topline-efficacy-data-from-patients-treated-with-rlf-100-aviptadil-under-the-us-fda-expanded-access-protocol-authorization-for-respiratory-failure-related-to-critical-covid-19-301150707.html
https://www.reuters.com/article/us-health-coronavirus-relief-hldg/relief-therapeutics-announces-supply-deals-while-awaiting-covid-19-trial-data-idUSKBN26L0NI
https://www.biospace.com/article/releases/relief-announces-capital-increase-from-its-final-tranche-of-the-share-subscription-facility-with-gem/?s=75
https://seekingalpha.com/news/3616368-neurorx-requests-emergency-use-of-rlfminus-100-in-covidminus-19
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/new-drug-rlf-100-shows-dramatic-recovery-in-covid-19-patients-suffering-respiratory-failure/articleshow/77384788.cms
https://www.pharmaceutical-technology.com/news/neurorx-fda-covid-fast-track/
https://www.globenewswire.com/news-release/2020/06/08/2044632/0/en/Relief-Therapeutics-and-NeuroRx-Expand-Clinical-Trial-of-RLF-100-to-All-Patients-with-Critical-COVID-19-and-Respiratory-Failure.html
https://www.globenewswire.com/news-release/2020/05/11/2030727/0/en/Relief-Therapeutics-Announces-Filing-of-IND-for-Phase-2-3-Clinical-Trial-of-Inhaled-RLF-100-Targeting-Early-COVID-19-Lung-Injury.html
https://www.clinicaltrialsarena.com/news/relief-aviptadil-covid-19-trial-us/
https://www.prnewswire.com/news-releases/relief-therapeutics-and-neurorx-inc-file-fda-ind-for-aviptadil-to-treat-covid-19-induced-respiratory-distress-301030267.html
https://www.prnewswire.com/il/news-releases/relief-therapeutics-and-neurorx-inc-file-fda-ind-for-aviptadil-to-treat-covid-19-induced-respiratory-distress-845943046.html
Market Place
Share 
